Pharmacoeconomic research of surgical treatment of juvenile nasopharyngeal angiofibroma: preoperative endovascularly occlusion classes

Introduction . Intraoperative control of bleeding during surgical treatment juvenile nasopharyngeal angiofibroma (JAN) remains controversial. There is no consensus as to the routine use preoperative embolization, given its high cost and inconsistent availability procedure in care centers. were publications devoted comprehensive pharmacoeconomic analysis vascular embolization (PVE) occlusion classes on JAN by time publication Aim. To evaluate value (non-embolized, incomplete complete) JAN. Materials methods A total 139 patients who underwent JNA resection 2013-2021 period identified. All these treated National Medical Research Center for Children's Hematology, Oncology Immunology named after Dmitry Rogachev. We evaluated outcomes, length stay (LOS) with prognostic factors using a multiple linear regression (MLR), cost-per-day (CPD), cost-minimization (CMA), cost-utility ratio (CUR), willingness pay (WTP) purchasing power parity (PWP). Results discusion Surgical transnasal endoscopic quaternary healthcare center, regardless degree presence/absence intraoperative blood transfusion, at willingness-to-pay threshold system Russian Federation. The most method absence (within clips placed larger diameter vessels). least transfusion. Conclusion results study emphasize significance rejection implementation standard risk-adapted algorithm indications embolization. Which particularly important resource allocations health policy decision making increase efficacy safety treatment.